Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceará, Brazil.
Post-Graduate Program in Pharmacology, Federal University of Ceara, Fortaleza, Ceará, Brazil.
Postgrad Med J. 2023 May 22;99(1170):286-295. doi: 10.1136/postgradmedj-2021-141375.
The aim of this study was to investigate the effect of CYB2B6 (c.516G>T, rs3745274), CYP2C9 (c.1075A>C, rs1057910) and UGT1A9 (c.98T>C, rs72551330) polymorphisms on the pharmacokinetics of single-drug propofol in adult patients undergoing intravenous sedation.
In this prospective clinical study, a total of 124 patients undergoing anaesthesia with propofol, as a single drug, were evaluated when undergoing colonoscopy procedure. Clinical variables were obtained from the patient's anamnesis prior to performing the anaesthetic procedure, in the moment of the patient's loss of consciousness, during the colonoscopy exam (recorded every 5 min) and in the awakening time.
Polymorphic genotypes for the rs3745274 and rs1057910 polymorphisms were associated with bispectral index, target-controlled infusion (TCI)/effector concentration of propofol and TCI/plasma concentration of propofol values. Based on multivariate analysis, it was observed that weight, age, surgery time, systolic blood pressure and the rs1057910 polymorphism corresponded to predictive values for the dose of propofol used. Weight (B = 4.807±0.897), age (B = 1.834±0.834) and duration of surgery (B = 8.164±1.624) corresponded to factors associated with increased propofol dose, while systolic blood pressure (B = -1.892±0.679) and the genotypes (AA vs CA) of the single nucleotide polymorphism (SNP) rs1057910 CYPP2C9 gene (B = -74.161±26.820) decreased the total dose of propofol used.
We concluded that the rs1057910 and rs3745274 polymorphisms affect the metabolism of propofol in patients exclusively submitted to this drug. Thus, the knowledge of the polymorphic genotypes of the CYPP2C9 and CYB2B6 genes may be predictive of different metabolising phenotypes, suggesting expected behaviours of BIS parameter in the anaesthetic procedure, which contributes to safer monitoring by anaesthesiologists during the clinical intervention.
本研究旨在探讨 CYP2C9(c.1075A>C,rs1057910)和 UGT1A9(c.98T>C,rs72551330)基因多态性对接受静脉镇静的成年患者单药异丙酚药代动力学的影响。
在这项前瞻性临床研究中,共评估了 124 例接受异丙酚单药麻醉的患者,这些患者在接受结肠镜检查时接受了麻醉。临床变量是在患者接受麻醉前的病史中获得的,在患者失去意识时、在结肠镜检查期间(每 5 分钟记录一次)和苏醒时间。
rs3745274 和 rs1057910 多态性的基因型与双频谱指数、异丙酚靶控输注(TCI)/效应浓度和异丙酚 TCI/血浆浓度有关。基于多变量分析,观察到体重、年龄、手术时间、收缩压和 rs1057910 多态性与异丙酚剂量的预测值有关。体重(B=4.807±0.897)、年龄(B=1.834±0.834)和手术时间(B=8.164±1.624)与异丙酚剂量增加有关,而收缩压(B=-1.892±0.679)和单核苷酸多态性(SNP)rs1057910 CYP2C9 基因的基因型(AA 与 CA)(B=-74.161±26.820)降低了异丙酚的总剂量。
我们得出结论,rs1057910 和 rs3745274 多态性影响仅接受该药物的患者异丙酚的代谢。因此,了解 CYP2C9 和 CYPB2B6 基因的多态基因型可能预测不同的代谢表型,提示在临床干预期间麻醉师对 BIS 参数的预期行为,有助于更安全的监测。